The Medicines Company (MDCO) : Investors lapped up stocks on upticks to the tune of $0.57 million in the Tuesdays trading session. The trading value on downticks was comparatively at $0.31 million and the uptick to downtick ratio of 1.81 indicates continuous buying by the bulls. The net money flow into the stock was $0.25 million. Upticks saw transactions worth $0.1 clearly indicating buying by large investors. The total money flow for block trades stood at $0.1 million, which is a positive for the stock in the long-term. The Medicines Company (MDCO) fell $0.05 during the day at $36.14, a drop of -0.14% over the previous days close. However, for the week, the stock is 3.55%, compared to the previous week.
The company Insiders own 7.9% of The Medicines Company shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of -30.41%. In an insider trading activity, Cox Christopher T, officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, executed a transaction worth $1,729,956 on June 8, 2016. A total of 45,985 shares were purchased at an average price of $37.62. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Shares of The Medicines Company appreciated by 8.86% during the last five trading days but lost 1.72% on a 4-week basis. The Medicines Company is up 13.66% in the last 3-month period. Year-to-Date the stock performance stands at -1.93%.
The Medicines Company (NASDAQ:MDCO): stock turned positive on Tuesday. Though the stock opened at $36.57, the bulls momentum made the stock top out at $37.07 level for the day. The stock recorded a low of $36.09 and closed the trading day at $36.62, in the green by 1.19%. The total traded volume for the day was 1,249,872. The stock had closed at $36.19 in the previous days trading.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.